AGEN Agenus Inc.
XNAS 6.45 DelayedStock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
AGEN
$6.45
—
Key stats
$6.45
- 52-Week Range
- $2.71 – $10.31
- YTD
- +99.69%
- Straddle Price
- $1.50
- P/C Vol Ratio
- 3.54
- Market Cap
- $0.3B
- Open
- $6.32
- Day Range
- $6.24 – $6.53
- Volume
- 427,386
- Prev Close
- $6.40
Fair Value
MODEL: LONG
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 5.15% |
| Beta vs SPY | 1.73 |
| Cost of Equity (CAPM) | 14.67% (VRP-adj) |
| WACC | 14.62% |
| Volatility Risk Premium | +75.1pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +30.0% |
| DCF Horizon | 10 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.10 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.1B |
| Return on Equity (TTM) | -46.1% |
| Book / Price | -110.5% |
| Gross Margin (TTM) | 99.3% |
| FCF Margin (TTM) | -79.5% |
| Quality Score | 2/6 — normal (10y DCF) |
| SMA 50 | $7.69 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $7.73 |
| Bollinger Width / SMA20 | 786.3% (drives anchor stability) |
| Net Debt | $-0.0B |
| Market Cap | $0B |
Peers used for multiples: ABUS, IRWD, OSPN, PAHC, PD, QNST, RIGL
(filtered from 8 ETF-co-members; sector bias active)
60-Day Conviction
88%
20-Day Fair Value
≈ by Nov 20, 2026
$6.55
α +0.8%
rank 89%
conviction
51%
40-Day Fair Value
≈ by Dec 21, 2026
$6.67
α +2.7%
rank 87%
conviction
78%
60-Day Fair Value
≈ by Jan 19, 2027
$6.73
α +3.6%
rank 87%
conviction
88%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | $15.48 | 15% | median 7.2× · 7 peers |
| Peer EV/EBITDA | $6.28 | 19% | median 9.8× · 7 peers |
| Peer P/B | n/a | 0% | median 3.1× · 6 peers |
| Peer P/S | $11.37 | 25% | median 2.7× · 7 peers |
| Market Anchor (SMA50) | $7.69 | 0% | stability 0% (BB-width) |
| Options Expected (B-L 30d) | $6.29 | 41% | 13 strikes · skew -0.36 |
As of 2026-10-22 · updated
Related
About
- Industry (SIC)
- BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836) · industry map
- Exchange
- XNAS
- Market Cap
- $0.3B
- Employees
- 81
- List Date
- 2000-02-04
- CIK
- 0001098972
- Next Earnings
- 2026-11-09 (After-Close)
- EPS Forecast
- $0.01 (2 est.)
- Headquarters
- Lexington, MA
- Homepage
- https://www.agenusbio.com
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may b…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 13.93% | -20.46% | 8.75% | -16.62% | 22.98% | -12.07% | -0.58% |
| Feb | 1.27% | -0.37% | -20.46% | 5.48% | -18.80% | 16.43% | -2.74% |
| Mar | -31.31% | -5.02% | -21.65% | -12.13% | -40.75% | 0.00% | -18.48% |
| Apr | 7.67% | -28.02% | -3.82% | 3.15% | 80.62% | 15.00% | 12.43% |
| May | 39.67% | -13.92% | 3.31% | 18.33% | 19.93% | -8.85% | 9.74% |
| Jun | 30.09% | 21.25% | 0.63% | -1.30% | 10.65% | -12.07% | 8.21% |
| Jul | -6.83% | 31.63% | 0.00% | -63.81% | 14.05% | 122.22% | 16.21% |
| Aug | 16.64% | 8.87% | -5.48% | -13.74% | -22.01% | -2.69% | -3.07% |
| Sep | -15.19% | -24.91% | -18.71% | 10.71% | -7.45% | 24.28% | -5.21% |
| Oct | -27.82% | 20.10% | -23.81% | -17.65% | 1.79% | -22.03%* | -11.57% |
| Nov | -28.25% | 7.57% | -6.44% | -15.56% | 14.86% | -- | -5.56% |
| Dec | 8.05% | -9.09% | 5.77% | -26.54% | -27.31% | -- | -9.82% |
| Total | -20.04% | -28.53% | -60.74% | -83.56% | -0.78% | 97.73% | -15.99% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $7.63
SMA 50: $7.68
SMA 200: $4.85
Current: $6.46
EMA 12: $6.84
EMA 26: $7.28
MACD: -0.4380 | Signal: -0.1697
BEARISH
ADX (14): 22.65
WEAK TREND
+DI: 18.04
−DI: 28.21
Momentum Oscillators
RSI (14): 39.67
NEUTRAL
Stoch %K: 13.94
Stoch %D: 9.63
Williams %R: -83.19
Volume & Volatility
BB Upper: $10.01
BB Lower: $5.24
NEUTRAL
OBV: 196,736,681
Vol SMA 20: 1,102,593
Vol ROC: -67.22%
ATR: $0.54
True Range: $0.29
HV 20: 108.0%
HV 30: 96.1%
HV 60: 97.1%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-23T00:00:00 – 2026-10-21T00:00:00
AI Analysis
LLM Stock Analysis Report
Executive Summary
Overall Assessment: BULLISH (Confidence Level: 8/10)
Key Drivers:
- Positive news sentiment surrounding immuno-oncology therapies and cancer drug pipeline
- Strong technical signals, including bullish MACD crossover and RSI neutral zone
- High volatility indicating potential for significant price moves
Primary Risks:
- High beta indicating increased market sensitivity and potential for sharp declines
- Options market pricing a significant move by expiration, suggesting high uncertainty
Investment Thesis: AGEN is an attractive buy opportunity due to its strong technical signals, positive news sentiment, and high volatility. However, investors should be cautious of the stock's high beta and potential for significant price swings.
Recent News Sentiment Impact: The recent news headlines have been overwhelmingly positive, contributing to the stock's bullish bias. The FDA tightening survival standards and immuno-oncology therapies gaining momentum are driving forces behind AGEN's upward trajectory.
Technical Analysis
Trend Direction:
- Short-term (1-4 weeks): Bullish
- Medium-term (1-3 months): Bullish
- Long-term (3-12 months): Bullish
Support/Resistance Levels:
- SMA 20: $7.70 (support)
- EMA 12: $7.85 (resistance)
- Upper Bollinger Band: $8.65 (resistance)
Momentum Signals:
- RSI: 50.27 (neutral)
- MACD: Bullish crossover
- Bollinger Bands: Neutral
Volume Analysis:
- Volume SMA 20: 1041850.80 (strong buying interest)
- On-Balance Volume (OBV): 182952464.60 (strong buying pressure)
News & Sentiment Analysis
Recent Headlines Summary: The recent news headlines have been overwhelmingly positive, highlighting the growth potential of immuno-oncology therapies and the FDA's tightening survival standards.
Sentiment Assessment: Positive sentiment dominates, with only one neutral headline contributing to a slight offset.
Catalyst Identification: The upcoming earnings report could be a significant catalyst for AGEN, potentially driving price movements based on the company's performance.
Market Narrative: The positive news sentiment aligns with the technical signals, suggesting a strong upward trend is likely to continue.
Risk & Volatility Assessment
Risk Assessment:
- Beta: 1.56 (high risk)
- Volatility Regime: High volatility indicates increased market sensitivity and potential for sharp declines
- Options Market Signals: IV rank of 54.2% suggests medium-high volatility, with options market pricing a significant move by expiration
Downside Protection: Support levels at SMA 20 ($7.70) provide some downside protection.
Market Context & Positioning
Sector Performance:
- Biotechnology sector performing well, driven by immuno-oncology therapies and cancer drug pipeline growth
Institutional Activity:
- Strong buying interest from institutions, reflected in volume patterns suggesting institutional support
Correlation Analysis:
- Correlation with SPY: 0.17 (low correlation indicates independence)
Relative Valuation:
- AGEN is trading within its historical range, with some upward momentum.
Key Levels & Action Items
Critical Price Levels:
- SMA 20 ($7.70): Support
- EMA 12 ($7.85): Resistance
- Upper Bollinger Band ($8.65): Resistance
Breakout/Breakdown Levels:
- Breakout above upper Bollinger Band ($8.65) could trigger significant price moves
- Breakdown below SMA 20 ($7.70) would indicate a loss of momentum
Time-Sensitive Catalysts:
- Upcoming earnings report (date TBA)
Risk Management:
- Set stop-loss levels at SMA 20 ($7.70) to manage risk
- Consider position sizing and scaling based on market conditions
Generated
News
All AGEN news →
Earnings History
16 of 23 under expected move
Avg Expected Move
19.11%
Avg Actual Move
7.14%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-03-15 | After-Close | 15.94% | 5.59% | 0.35x | Within |
| 2021-05-06 | After-Close | 0.62% | 8.87% | 14.31x | Exceeded |
| 2021-08-09 | After-Close | 11.09% | 3.89% | 0.35x | Within |
| 2021-11-09 | After-Close | 22.22% | 2.70% | 0.12x | Within |
| 2022-03-01 | After-Close | 1.12% | 18.53% | 16.54x | Exceeded |
| 2022-05-10 | After-Close | 10.63% | 9.04% | 0.85x | Within |
| 2022-08-09 | After-Close | 1.27% | 4.30% | 3.39x | Exceeded |
| 2022-11-08 | After-Close | 1.01% | 9.42% | 9.33x | Exceeded |
| 2023-03-14 | After-Close | 0.98% | 5.59% | 5.70x | Exceeded |
| 2023-05-09 | After-Close | 12.59% | 2.67% | 0.21x | Within |
| 2023-08-08 | After-Close | 22.95% | 2.40% | 0.10x | Within |
| 2023-11-07 | After-Close | 22.22% | 2.41% | 0.11x | Within |
| 2024-03-14 | After-Close | 22.81% | 9.95% | 0.44x | Within |
| 2024-05-07 | After-Close | 18.98% | 4.50% | 0.24x | Within |
| 2024-08-08 | Pre-Market | 21.65% | 3.94% | 0.18x | Within |
| 2024-11-12 | After-Close | 99.84% | 2.42% | 0.02x | Within |
| 2025-03-11 | After-Close | 31.71% | 9.02% | 0.28x | Within |
| 2025-05-12 | After-Close | 40.71% | 3.43% | 0.08x | Within |
| 2025-08-11 | Pre-Market | 10.42% | 11.04% | 1.06x | Exceeded |
| 2025-11-10 | After-Close | 18.41% | 1.43% | 0.08x | Within |
| 2026-03-16 | After-Close | 13.68% | 21.28% | 1.56x | Exceeded |
| 2026-05-11 | Pre-Market | 17.67% | 14.66% | 0.83x | Within |
| 2026-08-06 | After-Close | 21.03% | 7.08% | 0.34x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
AGEN Options Activity & IV Rank
Volatility Metrics
Current IV: —
7-DTE IV: —
Expected Move: $1.50
7-DTE Move: $1.50
Days to Exp: 29 (2026-11-20)
Options Flow
Call Volume: 82
Put Volume: 290
P/C Volume: 3.537
BEARISH
Call OI: 3,657
Put OI: 2,234
P/C OI: 0.611
Total OI: 5,891
ATM Options Pricing
ATM Call: $0.93
ATM Put: $0.57
Call %: 14.3%
Put %: 8.9%
Chain Summary
Chain Volume: 1,438
Chain OI: 17,270
Last Updated: 10/22/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 78th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
78%
vs own history
GEX tilt
+0.54
OI-weighted, today
Vanna tilt
+0.56
δ-sensitivity to IV
Charm tilt
-0.43
δ-decay vs time
Vanna tilt +0.56: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.43: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 10 ATM contracts, 3k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
No data
30 DTE / 10d
—
—
pts
EXTREME
ATM 103.2% / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)$1.50Oct 22
Beta Analysis
Risk Metrics
Beta: 1.4235
Alpha: 87.19%
Correlation: 0.1517
R-Squared: 2.3%
Stock Volatility: 119.7%
Market Volatility: 12.8%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
AGEN Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 32,248,500 (as of 2026-03-31)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
6 filers$399.88K notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Citadel Advisors LLC Custodian | $90.27K | 22.57% | 2026-06-30 |
| 2 | IMC-Chicago, LLC Custodian | $82.31K | 20.58% | 2026-06-30 |
| 3 | Susquehanna International Group, LLP Custodian | $77.42K | 19.36% | 2026-06-30 |
| 4 | Wolverine Trading, LLC Custodian | $63.28K | 15.83% | 2025-09-30 |
| 5 | Simplex Trading, LLC Custodian | $54.77K | 13.70% | 2026-06-30 |
| 6 | Jane Street Group, LLC Custodian | $31.82K | 7.96% | 2026-06-30 |
4 filers$203.80K notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | IMC-Chicago, LLC Custodian | $73.75K | 36.19% | 2026-06-30 |
| 2 | Citadel Advisors LLC Custodian | $62.73K | 30.78% | 2026-06-30 |
| 3 | Susquehanna International Group, LLP Custodian | $56.92K | 27.93% | 2026-06-30 |
| 4 | Simplex Trading, LLC Custodian | $10.40K | 5.11% | 2026-06-30 |
AGEN Insider Trading (Form 4)
Latest: 2026-10-02Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-10-02 | Timothy Wright | Director | Grant (A) | +1,178 RSU | — | EDGAR | |
| 2026-10-02 | Thomas L Harrison | Director | Award (A) | +4,443 | $6.89 | $30.6K | EDGAR |
| 2026-09-16 | Marco Tullio Marcucci | Director | Grant (A) | +7,500 opt | — | EDGAR | |
| 2026-08-12 | Garo H Armen | See Remarks | Grant (A) | +1,971,500 opt | — | EDGAR | |
| 2026-08-11 | Brian Corvese | Director | Grant (A) | +100,000 opt | — | EDGAR | |
| 2026-08-11 | Thomas L Harrison | Director | Grant (A) | +50,000 opt | — | EDGAR | |
| 2026-08-07 | Timothy Wright | Director | Grant (A) | +50,000 opt | — | EDGAR | |
| 2026-08-07 | Steven J O'Day | Chief Medical Officer | Grant (A) | +100,000 opt | — | EDGAR | |
| 2026-08-07 | Jennifer Buell | See Remarks | Grant (A) | +200,000 opt | — | EDGAR | |
| 2026-08-07 | Susan B Hirsch | Director | Grant (A) | +50,000 opt | — | EDGAR | |
| 2026-08-07 | Jennifer Buell | See Remarks | Grant (A) | +200,000 opt | — | EDGAR | |
| 2026-08-07 | Timothy Wright | Director | Grant (A) | +50,000 opt | — | EDGAR | |
| 2026-08-07 | Steven J O'Day | Chief Medical Officer | Grant (A) | +100,000 opt | — | EDGAR | |
| 2026-08-07 | Susan B Hirsch | Director | Grant (A) | +50,000 opt | — | EDGAR | |
| 2026-07-14 | Garo H Armen | See Remarks | Award (A) | +4,852 | $3.35 | $16.3K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
AGEN Insider Holdings
8 insiders · @ $6.46
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Garo H Armen | See Remarks | 402,406 | $2.60M | $7.81M | 259 | 2026-08-12 |
| 2 | Steven J O'Day | Chief Medical Officer | 57,116 | $369.2K | -$118.3K | 10 | 2026-08-07 |
| 3 | Thomas L Harrison | Director | 51,988 | $336.1K | $0 | 10 | 2026-10-02 |
| 4 | Christine M Klaskin | PFO & PAO | 23,480 | $151.8K | -$164.7K | 70 | 2025-06-30 |
| 5 | Jennifer Buell | See Remarks | 19,738 | $127.6K | -$12.2K | 25 | 2026-08-07 |
| 6 | Susan B Hirsch | Director | 5,436 | $35.1K | $0 | 26 | 2026-08-07 |
| 7 | Brian Corvese | Director | 4,604 | $29.8K | $0 | 28 | 2026-08-11 |
| 8 | Timothy Wright | Director | 2,520 | $16.3K | $13.4K | 92 | 2026-10-02 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
AGEN Board & Officers
As of SEC filings through Oct 2, 2026Directors 7
- Timothy Wright · since Dec 7, 2006
- Brian Corvese · since Mar 8, 2007
- Garo H Armen · listed since Jun 2019
- Susan B Hirsch · since Oct 8, 2020
- Jennifer Buell · listed since Jun 2024
- Thomas L Harrison · since Aug 7, 2024
- Marco Tullio Marcucci · since Aug 5, 2026
Officers 4
- Garo H Armen · Chairman, Chief Executive Officer and Principal Financial Officer · listed since Feb 2026
- Steven J O'Day · Chief Medical Officer · since Feb 10, 2021
- Christine M Klaskin · Pfo & Pao · listed since Nov 2019
- Jennifer Buell · Chairman of the Executive Counsel · listed since Apr 2026
Changes in the last 10 years (32)
| Aug 5, 2026 | Marco Tullio Marcucci became a director |
| May 12, 2026 | The company announced the departure of Austin Charette as Principal Accounting Officer in an SEC filing |
| Apr 28, 2026 | Jennifer Buell first listed as Chairman of the Executive Counsel in an SEC filing |
| Feb 9, 2026 | Garo H Armen listed as Chairman, Chief Executive Officer and Principal Financial Officer (previously Chairman & CEO) in SEC filings |
| Jan 8, 2026 | Austin Charette became Principal Accounting Officer |
| Jan 28, 2025 | Jennifer Buell no longer listed as Chairman Executive Council in SEC filings |
| Oct 30, 2024 | The company announced the departure of Ulf Wiinberg from the board in an SEC filing |
| Aug 7, 2024 | Thomas L Harrison became a director |
| Jun 20, 2024 | Jennifer Buell listed as Chairman Executive Council (previously COO and President) in SEC filings |
| Jun 20, 2024 | Jennifer Buell first listed as a director in an SEC filing |
| Dec 21, 2022 | The company announced the departure of Wadih Jordan from the board in an SEC filing |
| Feb 10, 2021 | Steven J O'Day became Chief Medical Officer |
| Dec 17, 2020 | Adam Krauss became Chief Legal Officer |
| Oct 8, 2020 | Susan B Hirsch became a director |
| Aug 27, 2020 | Paul N Clark became a director |
| Jun 18, 2020 | Incyte Corp reported in an SEC filing no longer being a 10% owner |
| Jun 17, 2020 | Jennifer Buell listed as COO and President (previously Chief Operating Officer) in SEC filings |
| Nov 7, 2019 | Christine M Klaskin listed as Pfo & Pao (previously VP, Finance) in SEC filings |
| Jun 21, 2019 | Garo H Armen first listed as a director in an SEC filing |
| Nov 14, 2018 | Jennifer Buell listed as Chief Operating Officer (previously Chief Communications Officer) in SEC filings |
| Nov 7, 2018 | Allison M Jeynes-Ellis became a director |
| Jul 12, 2018 | Evan Kearns became VP and General Counsel |
| Jun 21, 2018 | Christian Cortis became Chief Strategy Officer |
| Dec 14, 2017 | Ozer Baysal listed as Chief Commercial Officer (previously Chief Business Officer) in SEC filings |
| Dec 14, 2017 | Jennifer Buell listed as Chief Communications Officer (previously VP Research & External Affairs) in SEC filings |
| Jun 29, 2017 | Jennifer Buell became VP Research & External Affairs |
| Jun 29, 2017 | Alex Duncan became Chief Technology Officer |
| Apr 21, 2017 | Garo H Armen no longer listed as a director in SEC filings |
| Apr 12, 2017 | Garo H Armen first listed as a director in an SEC filing |
| Apr 4, 2017 | Robert Benjamin Stein reported in an SEC filing no longer being President R&D |
| Jan 26, 2017 | Jean-Marie Cuillerot became Chief Medical Officer |
| Dec 23, 2016 | Garo H Armen no longer listed as a director in SEC filings |
Not reported recently (10)
- Allison M Jeynes-Ellis · Last reported as a director in an SEC filing dated Apr 22, 2024
- Adam Krauss · Last reported as Chief Legal Officer in an SEC filing dated Jul 2, 2021
- Paul N Clark · Last reported as a director in an SEC filing dated Apr 5, 2021
- Evan Kearns · Last reported as VP and General Counsel in an SEC filing dated Dec 21, 2020
- Alex Duncan · Last reported as Chief Technology Officer in an SEC filing dated Jul 25, 2019
- Christian Cortis · Last reported as Chief Strategy Officer in an SEC filing dated Jul 25, 2019
- Shalini Sharp · Last reported as a director in an SEC filing dated Jun 22, 2018
- Karen Valentine · Last reported as Chief Legal Officer in an SEC filing dated Jun 22, 2018
- Ozer Baysal · Last reported as Chief Commercial Officer in an SEC filing dated Jun 22, 2018
- Jean-Marie Cuillerot · Last reported as Chief Medical Officer in an SEC filing dated Apr 4, 2017
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
ETF Holders
20 ETFs hold AGEN
20 shown · $29.96M total exposure · 0.01% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $12.5M | — | 2026-09-30 |
| 2 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.01% | $6.2M | $75.1B | 2026-10-20 |
| 3 | VXF Vanguard Extended Market ETF | Vanguard | 0.00% | $4.0M | — | 2026-09-30 |
| 4 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.01% | $2.2M | — | 2026-09-30 |
| 5 | IWN iShares Russell 2000 Value ETF | iShares (BlackRock) | 0.01% | $1.9M | $13.7B | 2026-10-20 |
| 6 | FDM First Trust Dow Jones Select MicroCap Index Fund | First Trust | 0.37% | $978,286 | $264.8M | 2026-10-20 |
| 7 | IWC iShares Micro-Cap ETF | iShares (BlackRock) | 0.06% | $744,328 | $1.2B | 2026-10-20 |
| 8 | VFMO Vanguard U.S. Momentum Factor ETF | Vanguard | 0.03% | $531,191 | — | 2026-10-20 |
| 9 | VTWV Vanguard Russell 2000 Value ETF | Vanguard | 0.02% | $299,588 | — | 2026-09-30 |
| 10 | IWO iShares Russell 2000 Growth ETF | iShares (BlackRock) | 0.00% | $292,566 | $13.6B | 2026-10-20 |
| 11 | RSSL Global X Russell 2000 ETF | Global X | 0.01% | $117,862 | — | 2026-10-21 |
| 12 | QQQS Invesco NASDAQ Future Gen 200 ETF | Invesco | 0.47% | $97,391 | — | 2026-10-20 |
| 13 | VTWG Vanguard Russell 2000 Growth ETF | Vanguard | 0.00% | $64,585 | — | 2026-09-30 |
| 14 | VTHR Vanguard Russell 3000 ETF | Vanguard | 0.00% | $33,166 | — | 2026-09-30 |
| 15 | ITWO ProShares Russell 2000 High Income ETF | ProShares | 0.01% | $14,163 | — | 2026-10-21 |
| 16 | URTY ProShares UltraPro Russell2000 | ProShares | 0.00% | $11,027 | — | 2026-10-21 |
| 17 | UWM ProShares Ultra Russell2000 | ProShares | 0.00% | $7,130 | — | 2026-10-21 |
| 18 | FSEG Fidelity Enhanced Small Cap Growth ETF | Fidelity | 0.04% | $2,722 | $7.7M | 2026-10-20 |
| 19 | HDG ProShares Hedge Replication ETF | ProShares | 0.00% | $294 | — | 2026-10-21 |
| 20 | RB ProShares Russell 2000 Dynamic Buffer ETF | ProShares | 0.01% | $102 | — | 2026-10-21 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
3.31
TTM Diluted EPS
$1.96
TTM Revenue
$123.87M
TTM Net Income
$64.39M
TTM Op. Cash Flow
$-87.53M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q1 '26 | 2026-03-31 | $33.74M | $39.17M | $1.02 | $-35.95M |
| Q4 '25 | 2025-12-31 | $34.20M | $-10.63M | — | $-16.62M |
| Q3 '25 | 2025-09-30 | $30.23M | $63.86M | $1.94 | $-14.74M |
| Q2 '25 | 2025-06-30 | $25.69M | $-28.01M | $-1.00 | $-20.22M |
| Q1 '25 | 2025-03-31 | $24.07M | $-25.32M | $-1.03 | $-25.62M |
| Q4 '24 | 2024-12-31 | $26.84M | $-45.91M | $-1.94 | $-28.65M |
| Q3 '24 | 2024-09-30 | $25.11M | $-66.44M | $-3.08 | $-53.29M |
| Q2 '24 | 2024-06-30 | $23.51M | $-53.13M | $-2.52 | $-38.18M |
| Q1 '24 | 2024-03-31 | $28.00M | $-61.94M | $-3.04 | $-38.19M |
| Q4 '23 | 2023-12-31 | $83.80M | $-46.34M | $-2.32 | $-40.40M |
| Q3 '23 | 2023-09-30 | $24.31M | $-62.25M | $-3.29 | $-65.23M |
| Q2 '23 | 2023-06-30 | $25.30M | $-69.07M | $-3.93 | $-60.04M |
Q1 2026 • period ending 2026-03-31 • filed 2026-05-11
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
3.31
P/B
—
P/S
1.69
EV/EBITDA
11.20
EV/Sales
1.41
ROE
—
ROA
34.5%
Div Yield
0.00%
FCF Yield
-41.79%
Debt/Equity
—
Current Ratio
—
Market Cap
$209.45M
as of 2026-10-22
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
6.82M
SI % of Float
16.15%
Days to Cover
5.66
Short Vol Ratio
64.0%
Free Float
42.23M
Float %
93.5%
Short interest 2026-09-30 • Short volume 2026-10-21 • Float 2026-09-22